摘要
目的:比较喹硫平和奋乃静治疗老年精神分裂症的疗效和安全性。方法:喹硫平组30例[男性13例,女性17例,年龄(67±s10)a,BPRS评分(44±8)分]用喹硫平200～400mg·d-1,po,bid;奋乃静组30例[男性14例,女性16例,年龄(64±7)a,BPRS评分(43±7)分]用奋乃静8～20mg·d-1,po,bid。临床疗效和不良反应以BPRS,TESS评分观察4wk。结果:喹硫平组总有效率为90%,奋乃静组为83%(P>0.05)。喹硫平组对兴奋躁动控制较好,与奋乃静组较高的锥体外系症状(23%)比较差异有显著意义(P<0.01),其他不良反应2组相仿,且程度较轻。结论:喹硫平与奋乃静疗效相似。喹硫平不良反应轻,病人耐受良好,适宜在老年病人中推广应用。
AIM： To compare the effectiveness and safety of quetiapine and perphenazine in the treatment of elderly schizophrenia. METHODS： Thirty patients （（M 13, F 17）, age （67±s 10） a, BPRS scores （44±8）） were treated with quetiapine 200-400 mg·d^-1, po, bid, Thirty patients [（M 14, F 16）, age （64±7） a, BPRS scores （43±7）] treated with perphenazine 8-20 mg·d^-1, po, bid. The clinical effects and adverse reactions were assessed by BPRS, TESS for 4 wk. RESULTS： The total effective rates of quetiapine group and perphenazine group were 90 % and 83 % respectively （ P 〉 0.05 ）. The exciting and mania were controlled better in quetiapine group. There was a significant difference in control of extrapyramidal system symptoms between the two groups, higher in perphenazine group（P 〈 0.01 ）. The other adverse reactions were mild and similar in two groups. CONCLUSION： Quetiapine and perphenazine possess similar efficacy in the treatment of eider schizophrenia. Quetiapine shows well tolerance and less adverse reactions especially suitable for the elderly and worthy to be recommended.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2005年第12期951-954,共4页
Chinese Journal of New Drugs and Clinical Remedies
